Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600255 | 1.00 | SMYD3 (0.33) | SMYD3ALDH1A1SMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL25149963 | 1.00 | SMYD3 (0.33) | SMYD3ALDH1A1SMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL4171489 | 0.97 | GNAI3 (0.33) | SMYD3ALDH1A1SMN1; SMN2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL4171485 | 0.97 | GNAI3 (0.33) | SMYD3ALDH1A1SMN1; SMN2GNAI3GNAO1 | |
| Oxalic Acid SCHEMBL28318237 | 0.87 | SMYD3 (0.38) | SMYD3ALDH1A1SMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL12855787 | 0.85 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL184319 | 0.85 | — | — | |
| SCHEMBL5674203 | 0.84 | — | — | |
| SCHEMBL5674209 | 0.84 | — | — | |
| SCHEMBL5674199 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240548-A | A kind of preparation method of Cariliprazine intermediate | 上虞京新药业有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| CN-111471021-B | Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| CN-115003671-A | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-5852023-A | Cyclohexylamino and cycloalkoxy nitrogen heterocycles, processes for their preparation, and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0817774-A1 | CYCLOHEXYLAMINO AND CYCLOHEXYLALKOXY NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS AND FUNGICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030345-A1 | CYCLOHEXYLAMINO AND CYCLOHEXYLALKOXY NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1996-10-03 | — | — | WO | disclosed |
| EP-0294668-B1 | (2-CYANO-2-OXIMINOACETYL)-AMINO ACID DERIVATIVES | BAYER AG (DE) | 1993-04-07 | — | — | EP | disclosed |
| EP-0294667-B1 | (2-CYANO-2-OXIMINOACETYL)-AMINO ACID DERIVATIVES | BAYER AG (DE) | 1993-03-17 | — | — | EP | disclosed |
| US-5189061-A | Fungicide | BAYER AKTIENGESELLSCHAFT (DE) | 1993-02-23 | — | — | US | disclosed |
| US-5026710-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4963548-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-16 | — | — | US | disclosed |
| EP-0294668-A2 | (2-cyano-2-oximinoacetyl)-amino acid derivatives | BAYER AG (DE) | 1988-12-14 | — | — | EP | disclosed |
| EP-0294667-A2 | (2-cyano-2-oximinoacetyl)-amino acid derivatives | BAYER AG (DE) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | SMYD3 2033/4885ALDH1A1 794/4885SMN1; SMN2 3353/4885 |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDK6, CDKL1, CDK3 | SMYD3 2203/4885ALDH1A1 2581/4885SMN1; SMN2 4257/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | SMYD3 2436/4885ALDH1A1 1739/4885SMN1; SMN2 30/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | SMYD3 3248/4885ALDH1A1 916/4885SMN1; SMN2 3122/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | SMYD3 2033/4885ALDH1A1 794/4885SMN1; SMN2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.